A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (NCT07221253)
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
Who can join: Review the eligibility criteria below.
Location: Research Site — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (177 Sites)
Showing the first 25 of 177 sites.
- Research Site — Birmingham, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
- Research Site — Duarte, California
- Research Site — Los Angeles, California
- Research Site — Orange, California
- Research Site — Palo Alto, California
- Research Site — Aurora, Colorado
- Research Site — Hartford, Connecticut
- Research Site — New Haven, Connecticut
- Research Site — Washington D.C., District of Columbia
- Research Site — Washington D.C., District of Columbia
- Research Site — Gainesville, Florida
- Research Site — Jacksonville, Florida
- Research Site — Marietta, Georgia
- Research Site — Chicago, Illinois
- Research Site — Chicago, Illinois
- Research Site — Indianapolis, Indiana
- Research Site — Louisville, Kentucky
- Research Site — Louisville, Kentucky
- Research Site — Baltimore, Maryland
- Research Site — Ann Arbor, Michigan
- Research Site — Detroit, Michigan
- Research Site — Rochester, Minnesota
- Research Site — Omaha, Nebraska
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Biliary Tract Cancer
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers — Pittsburgh, Pennsylvania
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) — Birmingham, Alabama
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer — Tucson, Arizona
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) — Mobile, Alabama
- XmAb20717 in Advanced Biliary Tract Cancers — Philadelphia, Pennsylvania
- A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) — Phoenix, Arizona
Explore by condition: All Biliary Tract Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.